Notice2026-06501
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 3, 2026
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 64 (Friday, April 3, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 64 (Friday, April 3, 2026)]
[Notices]
[Page 16964]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-06501]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases
(NIAID), an institute of the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is giving notice of the
invention listed below, which is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
opportunity should be directed to: Benjamin Hurley at 240-276-5489, or
<a href="/cdn-cgi/l/email-protection#8ae8efe4e0ebe7e3e4a4e2fff8e6eff3cae4e3e2a4ede5fc"><span class="__cf_email__" data-cfemail="6d0f0803070c0004034305181f0108142d030405430a021b">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Human Antibodies With Anti-Lymphocyte Specificities and Lytic Activity
Description of Technology
Antibody therapies that target human B cells are a promising way to
treat diseases like B-cell cancers and autoimmune conditions like lupus
and multiple sclerosis. Traditionally, these antibodies are made in
animals and modified to resemble human antibodies to reduce immune
rejection. Researchers in the Laboratory of Immunoregulation (LIR) at
the National Institute of Allergy and Infectious Diseases (NIAID) have
developed a new approach of using blood plasma from a patient with the
rare immune disorder idiopathic CD4 lymphocytopenia (ICL) to find
naturally occurring human antibodies.
By using advanced genetic sequencing, the researchers discovered
and reproduced several new antibodies that could effectively attack and
kill B-cell tumors, normal B cells, and T cells, demonstrating
potential for eliminating cancerous or disease-causing immune cells.
One potent antibody, NIH58.9, killed B cells at low concentrations of
0.01 nanomolar. These new antibodies may be used as treatments,
combined with other therapies, or engineered into special formats like
bispecific antibodies or antibody-drug conjugates.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Development of monoclonal antibody therapies, bispecific
antibodies, and antibody-targeted drugs for use in organ
transplantation, B-cell lymphomas, and autoimmune conditions.
Competitive Advantages
<bullet> First fully human IgM antibody that binds to and kills B cells
at concentrations as low as 0.01Nm.
<bullet> Versatile antibody that may be used directly, engineered as
IgG1 antibody, and possibly developed into bispecifics or antibody-drug
conjugates.
Development Stage
<bullet> Pre-Clinical
Inventors: Dr. Ainhoa P[eacute]rez-D[iacute]ez, Dr. Irini Sereti,
both of NIAID.
Intellectual Property: HHS Reference No. E-025-2025. U.S.
Provisional Patent Application 63/787,190, filed on April 11, 2025.
Licensing Contact: To license this technology, please contact
Benjamin Hurley at 240-276-5489, or <a href="/cdn-cgi/l/email-protection#3d5f5853575c5054531355484f5158447d535455135a524b"><span class="__cf_email__" data-cfemail="1d7f7873777c7074733375686f7178645d737475337a726b">[email protected]</span></a>, and
reference E-025-2025.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Benjamin Hurley at 240-276-5489, or
<a href="/cdn-cgi/l/email-protection#e486818a8e85898d8aca8c919688819da48a8d8cca838b92"><span class="__cf_email__" data-cfemail="761413181c171b1f18581e03041a130f36181f1e58111900">[email protected]</span></a>.
Dated: March 31, 2026.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2026-06501 Filed 4-2-26; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 3, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.